Searched for
DOMESTIC FORMULATION SALES
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 27%, according to analystsWe are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...
- Hexagon Nutrition shares list at 7% premium over IPO price on boursesHexagon Nutrition debuted at a premium of up to 7.2% over its IPO price, in line with grey market expectations. The Rs 138.9 crore issue wa...
- PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stakePrivate equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...
- Stock picks of the week; 5 stocks with consistent score improvement and upside potential of up to 25%Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...
- Hexagon Nutrition IPO Day 2: GMP signals 15% listing gain; Retail portion subscribed 2.43xHexagon Nutrition’s Rs 139 crore IPO saw strong retail demand on Day 2, with the retail portion subscribed 2.43 times. The grey market prem...
- Hexagon Nutrition IPO Day 1: 37% subscription, Grey market signals 27% listing gainHexagon Nutrition's IPO opened strongly on its first day. Retail investors showed significant interest, subscribing 62% of their quota. The...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Alkem Labs sees Rs 930 crore block deal as promoter family entities pare stake; Goldman, Morgan Stanley among key buyersAlkem Laboratories shares experienced significant block deals totaling Rs 930 crore. Promoter family entities divested shares to a group of...
- IPO Calendar: Investors to get 2 mainboard public offers this week after a month of lullIndia’s IPO market is set to revive with two mainboard issues, CMR Green Technologies and Hexagon Nutrition, opening this week after a lull...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsIf the US-Iran ceasefire holds, the markets may see some recovery. The movement of crude oil prices and its impact on the markets supports ...
- Hexagon Nutrition IPO opens June 5: Price band fixed at Rs 42-45; check key details hereHexagon Nutrition Limited is launching its Initial Public Offering on June 5, 2026. The company plans to raise Rs 138.87 crore through an O...
- Margin pressure, slower growth outlook may cap upside for Sun Pharma stockSun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Deepa Jewellers, Cotec Healthcare receive Sebi approval for IPOsDeepa Jewellers, a B2B hallmarked gold jewellery processor based in Hyderabad, and Cotec Healthcare, a pharmaceutical CDMO, both received S...
- Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formul...
- Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the J...
- Mankind Pharma profit jumps 30% on chronic therapy demand in Q4Mankind Pharma announced a significant 30 percent profit increase for the fourth quarter. This growth was fueled by strong demand for chron...
Load More
